Results 161 to 170 of about 28,326 (256)

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin, Katherina Alsina, Allison S. Betof, Joseph Birkett, Marcus O. Butler, George Cole Jr., Rizwan Haq, Florian A. Karreth, Vinit B. Mahajan, Rahul Marpadga, Prithvi Mruthyunjaya, Paul Nathan, Jonas A. Nilsson, Gary Palmer, Joseph J. Sacco, Takami Sato, Sarah Stanhope, Pang‐ning Teng, Kyleigh LiPira   +18 more
wiley   +1 more source

The utility of ctDNA in rectal cancer

The Oncologist
Gagandeep Brar, Pashtoon Murtaza Kasi
openaire   +2 more sources

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial. [PDF]

ESMO Open
Blaye C, Bidard FC, Hue L, Howarth K, Pierga JY, Dalenc F, Jacot W, Djerroudi L, Potonnier W, Dumas V, Lalet C, Maréchal M, Pulido M, Brunet M, Salabert L, Venat L, Maran-Gonzalez A, Saal LH, Franchet C, Birkeälv S, MacGrogan G, Bonnefoi H.   +21 more
europepmc   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Association of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta-Analysis. [PDF]

CNS Neurosci Ther
Yang S, Zhang Z, Dong H, Yu X, Zhu F, Yang S.   +5 more
europepmc   +1 more source

The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Dac DT, Tanaka H, Takami A, Espinoza JL.
europepmc   +1 more source

Narrative review: clinical application and challenges of circulating tumor DNA in treatment response evaluation and prognostic prediction for esophageal cancer. [PDF]

J Thorac Dis
Gu R, Liu T, Jin H, Wang X.
europepmc   +1 more source

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma. [PDF]

Cancer Med
Danno T, Nakamura S, Taguchi S, Fujii Y, Teshima T, Sato Y, Kawai T, Kobayashi Y, Nagaoka K, Ueda Y, Matoba R, Kakimi K, Kume H.   +12 more
europepmc   +1 more source

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer. [PDF]

Cancer Res Commun
Serrano-Serrano ML, Godfried Sie C, Bechter O, Pretelli G, Vieito M, Fontana E, Han CH, Castañón Álvarez E, Matos I, Pinato DJ, Moreno I, Eefsen RL, Plummer R, Dummer R, Prenen H, Sutton J, Cinato E, Schnetzler G, Keshelava N, Roller A.   +19 more
europepmc   +1 more source